Please select the option that best describes you:
Topics:
Gynecologic Cancers • Cervical Cancer • Medical Oncology • Immunotherapy • ASCO Journal Club
Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?
Does the phase II KN-158 provide sufficient evidence to change management?
Answer from: at Academic Institution
The phase II Keynote-158 indication is based on objective response of 14% in patients with PD-L1+ tumors. The US FDA approval is accelerated approval meaning that there needs to be a confirmatory trial - this is Keynote 826 which is ongoing.
Sign in or Register to read more